Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Endometrial stromal sarcoma

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492